Navigation Links
Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response

l protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for ABRAXANE(R), please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on The Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.

FORWARD-LOOKING STATEMENT

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securitie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation

Post Your Comments:
(Date:11/20/2009)...v. 20 The National Association of ...ed a new initiative in the war on methamphetamine.... multi-state electronic tracking program that enfo...) medicines containing pseudoephedrine in real-tim...is based on a system that was developed and tested...
(Date:11/20/2009).... 20 The Department of ...o members of priority groups that did not have pre...linics are being held statewide on Nov. 20-22. Fri... on Saturday, Nov. 21, will be 8 a.m. to 2 p.m. On...p.m. to 8 p.m. ,, Individuals in the recommend...
(Date:11/20/2009)... Reportlinker.com announces that a...talogue. ,, Pipettes & Pipettors - A Globa...ker.com/p0164373/Pipettes--Pipettors---A-Global-Ma...m_medium=pr&utm_campaign=prnewswire ,, Pi...rt of any research laboratory. Large-scale applica...
Breaking Medicine Technology:National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 2National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 3Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Teens as Cardiologists in Training 3A Program Swaps Backpacks for Stethoscopes 48958 1Teens as Cardiologists in Training 3A Program Swaps Backpacks for Stethoscopes 48958 2Teens as Cardiologists in Training 3A Program Swaps Backpacks for Stethoscopes 48958 3Teens as Cardiologists in Training 3A Program Swaps Backpacks for Stethoscopes 48958 4Psoriasis Raises Risk of Heart Attack Stroke Death 48954 1Psoriasis Raises Risk of Heart Attack Stroke Death 48954 2HIVMA supports public plan option to ensure patients needs are met 48950 1HIVMA supports public plan option to ensure patients needs are met 48950 2
...Phase II Testing Certification with Edifecs CORE T...at are now required in X12 Version 5010 , , BELLE...t it will, together with its partners CAQH and Har... lessons learned from the CORE Phase II Certificat...ed 5010 Rules, in a presentation at the HIMSS09 In...
...ovo Nordisk today announced that the Endocrinologi...ited States Food and Drug Administration (FDA) has... liraglutide, a once-daily human GLP-1 analogue. ...ated to the risk profile of liraglutide. , , ...upported that appropriate evidence of cardiovascul...
Other Medicine Technology:Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 2Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 3Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 4Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 5Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 2Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 3
(Date:11/20/2009).../PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals C...reholders will be held on Monday, December 21, 200...val of two special resolutions. The first special ... all or substantially all of the assets of NUCRYST...sset purchase agreement dated November 10, 2009 am...
(Date:11/20/2009)...0 Rates of infection by ...ate October, but the pandemic flu virus continues ...ups, including the elderly, according to a new rep... ), the world,s leading provider of diagnostic tes... recent Quest Diagnostics Health Trends(TM) Report...
(Date:11/20/2009)...swire-USNewswire/ -- The following is a statement ... Health Care Association: ,, "The Nevada Health...e Majority Leader Harry Reid for his leadership in...f protecting every Nevada seniors, ongoing access ...trength and viability of our state,s vital frontli...
(Date:11/20/2009)..., 2009Emergency medical service (EMS) providers in...diac arrests each year. Only 5 to 10 percent of p...ter quality cardiopulmonary resuscitation (CPR) pr...ted with better patient outcome. The Resuscitatio...l research network to study prehospital treatments...
(Date:11/20/2009)...is expected to continue, CDC says, , , ...the United States are seeing declines in H1N1 swin...day, and while the disease remains widespread in 4...last week. , "We are beginning to see some decl... there is still a lot of influenza everywhere," Dr...
Breaking Medicine News(10 mins):Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3
...he tragic drug trial that left six volunteers seri...ines for drug testing.// Southampton University re...he drugs firm AstraZeneca in a technique called "m...rug trial. "We can monitor at a local level ...
...ulie Brown, from Livingston has accused the NHS of...t she was still pregnant after undergoing treatmen...own's St John's hospital had told her that the fet...ant. "A scan on Monday showed my baby was still in...
... path breaking study from the Journal of Political...t bearing on how the child shapes //up in adulthoo...tions on health programs that seek to make changes...purposes is that whereas heredity is immutable, co...
...esearchers from Mayo Clinic have reported improved...linum toxin (BOTOX?) early after// the occurrence ...ovement from wrinkling the wound site by paralyzin... the early healing phase with the injection improv...
...esearchers have found that people who practice Tra...ce. In a research conducted among 12 healthy //lo...ontrols, researchers found that the people practic...ontrols practiced Transcendental Meditation for 5 ...
...esearchers at the University of Pennsylvania Schoo...llpox virus and the manner with which it attaches/...s a topoisomerase has become a very important drug...Frederic D. Bushman, PhD, Professor of Microbiolog...
Other Medicine News:Health News:Personal Growth and Success Dependent on Prenatal Health 2Health News:Appearance Of Facial Scars Improved By Botulinum Toxin 2Health News:Appearance Of Facial Scars Improved By Botulinum Toxin 3Health News:Appearance Of Facial Scars Improved By Botulinum Toxin 4Health News:Penn Researchers Throw Light on the Structure Of Smallpox Virus Protein 2
...Drug Screen Tests are available in 14 configuratio...Designed using Microgenics Antibody Technology, th...point of care immunoassay targeted to detect MDMA ...cross-reactivity to any isomer of methamphetamine ...
...ite test! QuickScreen™ multi-panel dip cards...our choice of any conceivable combination of 9 dif...r total flexibility for your drug testing program....-in timer tells you when to read the results. Our ...
Insure
...tely 500,000 people die each year of colon cancer ...mprovements (high contrast berium enema, colonosco...e in the success rate of curative treatment for co... past two decades. The chances of successful treat...
Medicine Products: